Analysis Archives - Page 4 of 9

New MGA Analysis of Biosimilar Coverage in Commercial Medical Benefit

Dec 8, 2022 | Analysis

A new MGA white paper from CEO Alex Brill and Principal Christy Robinson shows a positive outlook for biosimilar coverage in the commercial medical benefit.

Updated MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

Jul 14, 2022 | Analysis

MGA releases an updated report, “Biosimilar Market Opportunities in Ophthalmology.”

New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology

May 26, 2022 | Analysis

MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.”

Alex Brill to FTC: Claims That PBMs Raise Drug Prices are Unfounded

May 12, 2022 | Analysis

In response to the FTC’s request for information regarding the business practices of pharmacy benefit managers (PBMs) and their impact on pharmacies and consumers, MGA’s Alex Brill submitted a letter detailing his findings.

New Report from MGA Examines Impact of Rebates on Drug Pricing, Competition

Mar 1, 2022 | Analysis

MGA has released a new report today, “Understanding Drug Rebates and Their Role in Promoting Competition,” authored by founder and CEO Alex Brill.

Patent Thickets Constrain US Biosimilars Market

Dec 8, 2021 | Analysis

Biosimilars represent a significant cost-savings opportunity in the United States because they can introduce competition for some of the most expensive and widely used prescription drugs on the market: originator biologics. Several market and regulatory barriers have slowed biosimilar market entry and uptake in the United States.